By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Medicines Company v. Mylan Inc. et al.
1:11-cv-01285; filed February 23, 2010 in the Northern District of Illinois
• Plaintiff: The Medicines Company
• Defendants: Mylan Inc.; Mylan Pharmaceuticals Inc.; Bioniche Pharma USA, LLC
Infringement of U.S. Patent Nos. 7,582,727 ("Pharmaceutical Formulations of Bivalirudin and Process of Making the Same," issued September 1, 2009) and 7,598,343 (same title, issued October 6, 2009) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of The Medicines Company's Angiomax® (bivalirudin, used as an anticoagulant in patients with unstable angina undergoing percutaneous translurninal coronary angioplasty). View the complaint here.
Regeneron Pharmaceuticals, Inc. v. Genentech, Inc.
7:11-cv-01156; filed February 18, 2011 in the Southern District of New York
Declaratory judgment of non-infringement and/or invalidity of U.S. Patent Nos. 5,952,199 ("Chimeric Receptors as Inhibitors of Vascular Endothelial Growth Factor Activity, and Processes for Their Production," issued September 14, 1999), 6,100,071 ("Receptors as Novel Inhibitors of Vascular Endothelial Growth Factor Activity and Processes for Their Production," issued August 8, 2000), 6,383,486 ("Inhibitors of Vascular Endothelial Growth Factor Activity, Their Uses and Processes for Their Production," issued May 7, 2002), 6,897,294 (same title, issued May 24, 2005), and 7,771,721 ("Methods for Using Chimeric Vascular Endothelial Growth Factor Receptor Proteins," issued August 10, 2010) based on Regeneron's newly filed Biological License Application for its VEGF Trap for treating wet age-related macular degeneration. View the complaint here.
Comments